Skip to main content
. 2019 May 14;14(5):e0216954. doi: 10.1371/journal.pone.0216954

Fig 4. Kaplan-Meier curves of progression-free survival according to thyroid irAEs.

Fig 4

Patients censored within 1 month from the first administration of nivolumab were excluded from each cohort. (A) Results in the total cohort; (B) results of comparisons between the overt thyroid irAE group and the subclinical thyroid irAE group in the total cohort; (C) results in the cohort of lung cancer; (D) results in the cohort of malignant melanoma.